<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03802123</url>
  </required_header>
  <id_info>
    <org_study_id>IAB-CD8-201</org_study_id>
    <nct_id>NCT03802123</nct_id>
  </id_info>
  <brief_title>⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors</brief_title>
  <official_title>A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImaginAb, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImaginAb, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of repeat doses ⁸⁹Zr-Df-IAB22M2C and to&#xD;
      establish the relationship between ⁸⁹Zr-Df-IAB22M2C PET/CT lesion uptake with CD8+ cells by&#xD;
      immunohistochemical staining in patients with selected advanced and metastatic solid&#xD;
      malignancies who are scheduled to receive standard of care immunotherapy. The study will also&#xD;
      evaluate uptake of ⁸⁹Zr-Df-IAB22M2C by PET/CT in patients at baseline and on immunotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study and potential risks, all patients giving written&#xD;
      informed consent will be evaluated to determine eligibility for study entry. Up to 1 week&#xD;
      prior to initiation of immunotherapy, patients will receive an injection of ⁸⁹Zr-Df-IAB22M2C&#xD;
      (1.0 mCi) and will undergo PET/CT scanning to determine baseline uptake of ⁸⁹Zr-Df-IAB22M2C&#xD;
      in tumor lesions and reference tissues. Patients will receive an additional injection of&#xD;
      ⁸⁹Zr-Df-IAB22M2C (1.0 mCi) and PET/CT scan 4-6 weeks after starting immunotherapy&#xD;
      (on-therapy) to evaluate uptake of ⁸⁹Zr-Df-IAB22M2C in tumor lesions and reference tissues,&#xD;
      and to assess potential changes in uptake of ⁸⁹Zr-Df-IAB22M2C compared to the baseline scan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of ⁸⁹Zr-Df-IAB22M2C uptake in biopsied tumors with CD8+ cell measurement by immunohistochemistry (IHC)</measure>
    <time_frame>Baseline to 4-5 weeks after the start of immunotherapy</time_frame>
    <description>Analyze ⁸⁹Zr-Df-IAB22M2C uptake in biopsied tumors as determined by SUV-based quantitative measures (SUVmax, SUVpeak, SUVmean, CD8 tumor volume, and tumor:reference tissue ratio) with CD8+ cell measurement determined by IHC from biopsy samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Time of infusion of ⁸⁹Zr-Df-IAB22M2C (Visit 2 Day 1) through 4-5 weeks after the second infusion of ⁸⁹Zr-Df-IAB22M2C</time_frame>
    <description>The incident and severity of adverse events per CTCAE criteria will be recorded following repeat doses of ⁸⁹Zr-Df-IAB22M2C. ria, changes in laboratory test results, vital signs, and 12- lead electrocardiogram findings prior to and within 1 hour post injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Signs and symptoms of infusion reactions</measure>
    <time_frame>Time of infusion of ⁸⁹Zr-Df-IAB22M2C (Visit 2 Day 1) through 4-5 weeks after the second infusion of ⁸⁹Zr-Df-IAB22M2C</time_frame>
    <description>Signs and symptoms of infusion reactions following repeat doses of ⁸⁹Zr-Df-IAB22M2C will be assessed evaluating the incidence and severity of local and systemic signs and symptoms of infusion reactions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in WBC differential including percentages of total WBC and absolute counts: (neutrophils, immature neutrophils, lymphocytes, monocytes, eosinophils, basophils) laboratory values compared to baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>WBC differential including percentages of total WBC and absolute counts: (neutrophils, immature neutrophils, lymphocytes, monocytes, eosinophils, basophils) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in mean corpscular volume (fL) laboratory values compared to baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>mean corpscular volume (fL) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in hematocrit (%) laboratory values compared with baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>hematocrit (%) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in hemoglobin (g/dL) laboratory values compared with baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>hemoglobin (g/dL) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in platelet count (thousands/ul) laboratory values compared with baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>platelet count (thousands/ul) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in WBC count (thousands/ul) laboratory values compared with baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>WBC count (thousands/ul) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in RBC count (millions/uL) laboratory values compared with baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>RBC count (millions/uL) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in blood glucose (mg/dL) laboratory values compared with baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>blood glucose (mg/dL) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in chloride (mmol/L) laboratory values compared with baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>chloride (mmol/L) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in potassium (mmol/L) laboratory values compared with baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>Potassium (mmol/L) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in sodium (mmol/L) laboratory values compared with baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>sodium (mmol/L) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in uric acid (mg/dL) laboratory values compared with baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>uric acid (mg/dL) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in serum creatinine (mg/dL) laboratory values compared with baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>serum creatinine (mg/dL) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in GGT (U/L) laboratory values compared with baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>GGT (U/L) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in BUN (mg/dL) laboratory values compared with baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>BUN (mg/dL) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in LDH (U/L) laboratory values comapared with baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>LDH (U/L) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bilirubin, direct and total (mg/dL) laboratory values</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>Change/shifts in Bilirubin, direct and total (mg/dL) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ALP laboratory values</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>Change/shifts in ALP (U/L) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ALT laboratory values</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>Change/shifts in ALT (U/L) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AST laboratory values</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>Change/shifts in AST (U/L) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12-Lead electrocardiogram</measure>
    <time_frame>Within 60 minutes post-infusion (study visits 2 and 5)</time_frame>
    <description>Proportion of subjects with abnormal electrocardiogram findings prior to and within 1 hour post injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of blood pressure</measure>
    <time_frame>15 +/- 5 minutes prior to infusion and within 60 minutes post-infusion (study visits 2 and 5) and 4-6 weeks after 2nd infusion (study visit 8)</time_frame>
    <description>Changes/shifts in blood pressure (systolic and diastolic)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of heart rate</measure>
    <time_frame>15 +/- 5 minutes prior to infusion and within 60 minutes post-infusion (study visits 2 and 5) and 4-6 weeks after 2nd infusion (study visit 8)</time_frame>
    <description>Changes/shifts in heart rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of respiration rate</measure>
    <time_frame>15 +/- 5 minutes prior to infusion and within 60 minutes post-infusion (study visits 2 and 5) and 4-6 weeks after 2nd infusion (study visit 8)</time_frame>
    <description>Changes/shifts in respiration rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of temperature</measure>
    <time_frame>15 +/- 5 minutes prior to infusion and within 60 minutes post-infusion (study visits 2 and 5) and 4-6 weeks after 2nd infusion (study visit 8)</time_frame>
    <description>Changes/shifts in temperature</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Baseline and On-treatment ⁸⁹Zr-Df-IAB22M2C uptake and distribution in tumors and lymphoid organs, and measurement of change between the paired observations</measure>
    <time_frame>5 weeks</time_frame>
    <description>Assessment of Baseline and On-treatment ⁸⁹Zr-Df-IAB22M2C uptake and distribution in tumors and lymphoid organs, and measurement of change between the paired observations as determined by:&#xD;
Tumor uptake analysis as described by visual scoring scales&#xD;
Lymph node chain visibility defined as location and number of nodes in lymph node chains identified with elevated ⁸⁹Zr-Df-IAB22M2C activity.&#xD;
SUV-based quantitative analysis (e.g. SUVmax, SUVpeak, SUVmean, CD8 tumor volume (volume of tumor tissues with increased CD8 uptake with SUV &gt;40% SUVmax), and Tumor:Reference ratios&#xD;
Visual and SUV-based quantitative analysis (e.g. SUVmax, SUVpeak, SUVmean) in tumor and reference tissue including lymph nodes, spleen, and bone marrow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of change in ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake in biopsied tumors as determined by SUV-based quantitative analysis</measure>
    <time_frame>7 weeks</time_frame>
    <description>Measurement of change in ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake in biopsied tumors as determined by SUV-based quantitative analysis (e.g. SUVmax, SUVpeak, SUVmean, CD8 tumor volume (volume of tumor tissues with increase CD8 uptake with SUV &gt; 40% SUVmax) and Tumor: Reference ratio from Baseline to On- Treatment PET scans and correlation with change in CD8+ T cells as determined by IHC from biopsy samples obtained prior to and 4 to 7 weeks after the start of immunotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of biodistribution patterns of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) on PETbaseline and PETTx and any changes in biodistribution between baseline and On-Treatment.</measure>
    <time_frame>7 weeks</time_frame>
    <description>Description of biodistribution patterns of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) on PETbaseline and PETTx and any changes in biodistribution between baseline and On-Treatment. PETbaseline and PETTx scans compared to change in CD8+ T cells in tumor lesions by IHC if the same lesion was biopsied at Baseline and On-Treatment visits</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluation of the variance in gene expression profiles in subjects prior to and On-treatment as measured in whole blood by Nanostring analysis.</measure>
    <time_frame>7 weeks</time_frame>
    <description>Evaluation of the variance in gene expression profiles in subjects prior to and On-treatment as measured in whole blood by Nanostring analysis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation of visual and quantitative ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake in tumor lesions with change in CD8+ T cells as determined by IHC from biopsy samples obtained prior to and 4 to 7 weeks after the start of immunotherapy.</measure>
    <time_frame>7 weeks</time_frame>
    <description>Correlation of visual and quantitative ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake in tumor lesions with change in CD8+ T cells as determined by IHC from biopsy samples obtained prior to and 4 to 7 weeks after the start of immunotherapy.</description>
  </other_outcome>
  <other_outcome>
    <measure>Estimation of positive predictive value, negative predictive value, sensitivity and specificity of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) PET for detecting CD8+ T cells as determined by IHC.</measure>
    <time_frame>7 weeks</time_frame>
    <description>Estimation of positive predictive value, negative predictive value, sensitivity and specificity of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) PET for detecting CD8+ T cells as determined by IHC.</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of changes in ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake and distribution from baseline to 5-7 days start of immunotherapy if available.</measure>
    <time_frame>7 weeks</time_frame>
    <description>Assessment of changes in ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake and distribution from baseline to 5-7 days start of immunotherapy if available.</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake with clinical outcomes (response rates, duration of response, disease stability rate and PFS at defined intervals as determined by the local investigator.</measure>
    <time_frame>18 months</time_frame>
    <description>Correlation of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake with clinical outcomes</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake with radiologic responses</measure>
    <time_frame>7 weeks</time_frame>
    <description>Correlation of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake with radiologic responses based upon:&#xD;
Correlation of subject response by RECIST 1.1 compared to visual and quantitative SUVbased analysis&#xD;
Correlation of RECIST target lesion response as determined by best change in lesion diameter while on immunotherapy compared to visual and quantitative SUV based analysis at baseline and On-treatment PET/CT scans.</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) tumor and lymph node uptake with immune infiltrates and other molecular biomarker (CD8) expression by IHC</measure>
    <time_frame>7 weeks</time_frame>
    <description>Correlation of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) tumor and lymph node uptake with immune infiltrates and other molecular biomarker (CD8) expression by IHC</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation of the 89Zr-Df-IAB22M2C(CD8 PET Tracer) uptake on a subset of PETbaseline and PETtx scans that have been virtually reconstructed with lower theoretical doses of 8⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) with CD8+ T cells from IHC analysis.</measure>
    <time_frame>7 weeks</time_frame>
    <description>Correlation of the 89Zr-Df-IAB22M2C(CD8 PET Tracer) uptake on a subset of PETbaseline and PETtx scans that have been virtually reconstructed with lower theoretical doses of 8⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) with CD8+ T cells from IHC analysis.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Positron-Emission Tomography</condition>
  <condition>Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>⁸⁹Zr-Df-IAB22M2C Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A dose of 3 mCi (±20%) of ⁸⁹Zr-Df-IAB22M2C between 0.5 mg to 1.5 mg of API will be administered intravenously over 5-10 minutes, within one week prior to the onset of immunotherapy, and 5 to 6 weeks after start of IOT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>⁸⁹Zr-Df-IAB22M2C</intervention_name>
    <description>⁸⁹Zr-Df-IAB22M2C CD8 T cell tracer for Positron Emission Tomography (PET)</description>
    <arm_group_label>⁸⁹Zr-Df-IAB22M2C Infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants will be eligible for enrollment in the study only if they meet ALL of the&#xD;
        following criteria:&#xD;
&#xD;
          1. 1. Patients with advanced or metastatic Melanoma, Non-Small Cell Lung Cancer, Renal&#xD;
             Cell Carcinoma or Squamous Cell Carcinoma of the Head and Neck with at least one&#xD;
             non-radiated lesion, who are scheduled to begin standard of care immunotherapy.&#xD;
&#xD;
          2. • At least 1 non radiated measurable lesion documented on CT/, MRI (per RECIST&#xD;
             criteria 1.1) or are FDG avid on FDG-PET within 45 days prior to first&#xD;
             89Zr-Df-IAB22M2C (CD8 PET Tracer) infusion.&#xD;
&#xD;
          3. At least 1 non-cutaneous lesion that is accessible, per investigator's assessment, and&#xD;
             eligible for biopsy. If only a single RECIST measurable lesion is present,&#xD;
             investigator to determine if the tumor biopsy could interfere with RECIST assessments&#xD;
             of response.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.&#xD;
&#xD;
          5. Meeting all clinical safety lab values per institution's standard of care, or&#xD;
             Investigator's discretion, for patients receiving cancer treatment.&#xD;
&#xD;
          6. Age ≥ 18 years.&#xD;
&#xD;
          7. Ability to understand the purposes and risks of the trial and has signed an&#xD;
             IRB-approved informed consent form.&#xD;
&#xD;
          8. Willingness and ability to comply with all protocol required procedures.&#xD;
&#xD;
          9. For men and women of child-producing potential, use of effective double barrier&#xD;
             contraceptive methods during the study, up to 30 days after the last administration of&#xD;
             the investigational product.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects will NOT be eligible for enrollment in the study if they meet ANY of the following&#xD;
        criteria:&#xD;
&#xD;
          1. Serious nonmalignant disease or conditions that in the opinion of the investigator&#xD;
             and/or ImaginAb could compromise protocol objectives.&#xD;
&#xD;
          2. Patients with a single RECIST measurable lesion, biopsy of which, per investigator's&#xD;
             assessment, is likely to interfere with RECIST assessments of response.&#xD;
&#xD;
          3. Patients who have any splenic disorders, or had splenectomy, that in the opinion of&#xD;
             the investigator and/or ImaginAb could compromise protocol objectives.&#xD;
&#xD;
          4. Pregnant women or nursing mothers.&#xD;
&#xD;
          5. 5. Life expectancy &lt; 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ron Korn, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>ImaginAb, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>William Le, M.S.</last_name>
    <phone>(310) 730-5812</phone>
    <email>wle@imaginab.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama-Birmingham Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan McConathy, MD, PhD</last_name>
      <phone>205-996-7115</phone>
      <email>jmcconathy@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan McConathy, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Carroll, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eddy Yang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gagandeep Choudhary, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marty Conry, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pradeep Bhambhvani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lisle Nabell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sam Galgano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco Robert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janis O'Malley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sharon White, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suzy Lapi, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CARTI Cancer Center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Hays, MD</last_name>
      <phone>501-906-3000</phone>
      <email>david.hays@carti.com</email>
    </contact>
    <investigator>
      <last_name>David Hays, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jamie Burton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rhonda Gentry, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ryan Hall, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariann Harrington, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kewen Jauss, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Omer Khalil, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lawrence Mendelsohn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Balagopalan Nair, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kamal Patel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Grace Raja, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Sneed, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diane Wilder, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope (City of Hope National Medical Center, City of Hope Medical Center)</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim A Margolin, MD</last_name>
      <phone>626-256-4673</phone>
      <email>kmargolin@coh.org</email>
    </contact>
    <investigator>
      <last_name>Kim A Margolin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arya Amini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ammar A Chaudhry, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Savita Dandapani, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tanya B Dorff, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Morganna Freeman, DO, FACP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erminia Massarelli, MD, PhD, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria L Parayno, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sagus Sampath, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey YC Wong, MD, FASTRO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dave M Yamauchi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keck Hospital of USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Thomas, MD</last_name>
      <phone>949-764-6130</phone>
      <email>jacob.thomas@med.usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LAC + USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Thomas, MD</last_name>
      <phone>949-764-6130</phone>
      <email>jacob.thomas@med.usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Thomas, MD</last_name>
      <phone>949-764-6130</phone>
      <email>jacob.thomas@med.usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Thomas, MD</last_name>
      <phone>949-764-6130</phone>
      <email>jacob.thomas@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Jacob Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Wayne Cancer Institute at Providence Saint John's Health Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven O'Day, MD</last_name>
      <phone>310-829-8317</phone>
      <email>ODayS@jwci.org</email>
    </contact>
    <investigator>
      <last_name>Steven O'Day, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Przemyslaw Twardowski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Trevan Fischer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Srinivas Peddi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Graham, MD, PhD</last_name>
      <phone>319-356-4302</phone>
      <email>michael-graham@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Graham, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yusuf Menda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janet Pollard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Parren McNeely, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Bushnell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jiefu Zheng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohammed Milhem, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yousef Zakharia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rohan Garje, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Douglas Laux, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandeep Laroia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brendan O'Shea, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohammad Amarneh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute (DFCI)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annick D Van den Abbeele, MD</last_name>
      <phone>617-632-3580</phone>
      <email>abbeele@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Annick D Van den Abbeele, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heather Jacene, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen F Hodi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Ott, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rizwan Haq, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Buchbinder, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Izar, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Megan Insco, MD, Phd</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Liu, MD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jill Gormley, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tera Feldman, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meredith Davis, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amanda Livengood, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Gargano, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Shields, PhD, MD</last_name>
      <phone>313-576-8735</phone>
      <email>shieldsa@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Anthony Shields, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lawrence Flaherty, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisabeth Heath, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hirva Mamdani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Misako Nagasaka, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ammar Sukari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ulka Vaishampayan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amy Weise, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barry A Siegel, MD</last_name>
      <phone>314-747-7222</phone>
      <email>siegelb@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Barry A Siegal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>George Ansstas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Douglas Adkins, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Morgansztern, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Farrokh Dehdashti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Russell Pachynski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Frye, CNMT, CCRC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Helen Kaemmerer, CCRC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Andrew Postow, MD</last_name>
      <phone>646-888-4589</phone>
      <email>Postowm@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Michael Andrew Postow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jedd Wolchok, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Chapman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margaret Callahan, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Shoushtari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Perelman School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Farwell, MD</last_name>
      <phone>215-662-7750</phone>
      <email>michael.farwell@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Farwell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dan Pryma, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Austin Pantel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charu Aggarwal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance/ University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine L Chen, MD</last_name>
      <phone>206-606-2449</phone>
      <email>dlchen7@uw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 19, 2018</study_first_submitted>
  <study_first_submitted_qc>January 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2019</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PET/CT</keyword>
  <keyword>⁸⁹Zr-Df-IAB22M2C</keyword>
  <keyword>CD8</keyword>
  <keyword>Imaging</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

